Welcome to our dedicated page for USANA HEALTH SCIENCES SEC filings (Ticker: USNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
USANA Health Sciences, Inc. filings document financial results, management commentary and Regulation FD disclosures for a health and wellness products company. Form 8-K reports cover quarterly and annual results, preliminary sales information, guidance, exhibits and conference-call materials tied to the company’s operating updates.
Proxy and governance filings address director elections, board matters, executive compensation, equity awards and pay-versus-performance disclosure. Other material-event reports document leadership changes, transition agreements and compensatory arrangements, providing formal records of governance and management structure for USANA Health Sciences.
USNA submitted a Form 144 notice reporting proposed sales of specified restricted common stock. The filing lists multiple lots by grant/issue date and share count, with transactions routed through Morgan Stanley Smith Barney LLC and the principal market shown as NYSE.
Examples include 1,775 shares dated 02/08/2025 and 1,420 shares dated 02/06/2025. The filing provides lot-level detail rather than a single aggregate offering total.
USANA Health Sciences' Chief Financial Officer, Doug G. IIEKKING, reported selling 5,360 shares of the company’s Common Stock in an open-market transaction. The sale occurred at an average price of $18.7525 per share. Following this transaction, his directly held Common Stock position reported in this filing is zero shares.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice reporting proposed sales of restricted common stock of USNA. The form lists multiple planned dispositions by the issuer category on 02/06/2026, 02/07/2026, 02/08/2026, and 02/27/2026 with reported share amounts of 965, 619, 1,338, and 2,438, respectively.
USANA Health Sciences director Gilbert A. Fuller reported an open-market sale of 1,057 shares of USANA common stock. The trade on May 22, 2026 was executed at a weighted average price of $18.6648 per share, within a price range of $18.62 to $18.775. Following this transaction, the filing shows Fuller holding 0 directly owned shares of USANA common stock.
USANA Health Sciences reported the results of its Annual Meeting of Shareholders held on May 20, 2026. Shareholders representing 16,468,210 shares, about 89% of outstanding common stock, were present in person or by proxy, indicating strong participation.
All eight director nominees were elected, each receiving over 13.6 million votes in favor, with more than 2.1 million broker non-votes recorded for each seat. Shareholders also ratified the selection of KPMG LLP as independent registered public accounting firm for fiscal 2026, with 16,286,742 votes for.
On an advisory basis, shareholders approved the company’s executive compensation, with 13,811,489 votes for, 509,777 against, and 13,996 abstentions, along with 2,132,948 broker non-votes, signaling broad support for current pay practices.
USANA Health Sciences reported Q1 2026 net sales of $250.2 million, essentially flat year over year as Core Nutritional and Hiya declines were offset by strong growth at Rise. Core Nutritional sales were $204.4 million, down 3.0%, while Hiya fell 13.3% to $32.2 million and Rise jumped 740.7% to $13.7 million on the Protein Pop rollout.
Consolidated gross margin slipped to 76.2% from 79.0%, pressured by lower‑margin Rise and production inefficiencies in Core Nutritional. Net earnings attributable to USANA declined to $7.5 million from $9.4 million, with diluted EPS at $0.41 versus $0.49, reflecting lower operating margin and a higher 55.0% effective tax rate. Core Nutritional active Customers decreased 12.0% to 404,000, while USANA ended the quarter with $162.8 million in cash and cash equivalents and $14.0 million drawn on a $75 million revolving credit facility.
WOOD TIMOTHY E reported acquisition or exercise transactions in this Form 4 filing.
USANA Health Sciences director Timothy E. Wood received an equity grant of 6,527 restricted stock units. Each unit represents a right to receive one share of USANA common stock if it vests. The award vests in four equal 25% installments on July 23, 2026, October 22, 2026, January 21, 2027, and April 22, 2027. After this grant, Wood holds 6,527 restricted stock units directly.
Nixon J Scott reported acquisition or exercise transactions in this Form 4 filing.
USANA Health Sciences director J Scott Nixon received a grant of 6,527 restricted stock units. Each unit represents a contingent right to receive one share of USANA common stock. The restricted stock units vest 25% on July 23, 2026, October 22, 2026, January 21, 2027, and April 22, 2027. Following this award, Nixon holds 6,527 restricted stock units directly, reflecting a routine equity-based compensation grant rather than an open-market purchase or sale.
Pelosi Peggie reported acquisition or exercise transactions in this Form 4 filing.
USANA Health Sciences director Peggie Pelosi received a grant of restricted stock units. She was awarded 6,527 restricted stock units, each representing a right to receive one share of USANA common stock. The units vest in four equal 25% installments on July 23, 2026, October 22, 2026, January 21, 2027, and April 22, 2027.
Fleming John Turman reported acquisition or exercise transactions in this Form 4 filing.
USANA Health Sciences director John Turman Fleming reported receiving a grant of 6,527 restricted stock units, each representing a contingent right to one share of USANA common stock. All 6,527 units were newly awarded and held directly after the transaction.
The restricted stock units vest in four equal 25% installments on July 23, 2026, October 22, 2026, January 21, 2027, and April 22, 2027, tying the director’s compensation to the company’s longer-term performance and service over this period.